🌟 Join us at The Liver Meeting 2024! 🌟 📍 Visit the Sonic Incytes at booth 1450 to experience the latest in liver health technology with Velacur. Learn how Velacur can help transform your approach to managing Metabolic Associated Steatotic Liver Disease (MASLD). ✅ Hands-on demos ✅ In-depth insights into liver imaging advancements ✅ Meet our experts ready to discuss your practice needs 📅 Don’t miss out! Stop by our booth to discover how Sonic Incytes is advancing liver health for better outcomes. See you there! #TheLiverMeeting #LiverHealth #Velacur #SonicIncytes #MASLD #Hepatology
Sonic Incytes Medical Corp.
Medical Equipment Manufacturing
Vancouver, BC 2,227 followers
Creators of VELACUR: point-of-care AI guided ultrasound elastography for chronic liver diseases such as MASLD and MASH
About us
Sonic Incytes is committed to enhancing patient care through innovative diagnostic solutions. The company's flagship product, Velacur™, equips physicians with an advanced liver imaging tool to help manage the growing epidemic of fatty liver disease. Velacur offers real-time, AI guided quantification of the two key markers for fatty liver disease: liver stiffness and attenuation. With real-time results, a low up-front cost and AI guidance, VELACUR makes liver imaging at the point of care affordable and accessible.
- Website
-
http://www.sonicincytes.com
External link for Sonic Incytes Medical Corp.
- Industry
- Medical Equipment Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Vancouver, BC
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
1788 W 5th Ave
Suite 309
Vancouver, BC V6J 1P2, CA
Employees at Sonic Incytes Medical Corp.
Updates
-
Sonic Incytes Medical Corp. reposted this
We're offer Velacur™ liver imaging at most of our Tidewater, VA region offices, now including our Chesapeake office. Velacur is a quick, painless scan that measures liver stiffness and fat content. This convenient in-office tool helps us assess and manage chronic liver disease including nonalcoholic fatty liver disease, now known as metabolic dysfunction-associated steatotic liver disease. Learn more how about we're using Velacur to treat our patients: https://bit.ly/49pqDoB
-
-
Sonic Incytes Medical Corp. reposted this
Chief Medical Officer (CMO), Director of the Steatotic Liver Program. Arizona Liver Health
Join us today for a great discussion on using NITs to identify patients for Rx and clinical trials with the one and only Alina Allen. Medscape Arizona Liver Health Nick Engelke Michelle Long Madrigal Pharmaceuticals Novo Nordisk Echosens CIMA Sciences, LLC Fibronostics Kevin Murrey Sonic Incytes Medical Corp.
Join us every Monday in October for the latest in metabolic dysfunction-associated steatohepatitis(MASH)! In our final episode, our experts will talk through the guidelines for the identification and treatment of MASH. Be sure to tune in! - - - - - Moderator: Naim Alkhouri, MD, FAASLD Chief Medical Officer Director Steatotic Liver Program Arizona Liver Health (ALH) Phoenix, Arizona Faculty: Alina Allen, MD, MS Associate Professor of Medicine Mayo Clinic Rochester, Minnesota - - - - - Developed and funded by Medscape. Click the link to view the Accreditation and Disclosure details. https://lnkd.in/enakg5d4
Monster MASH Mondays: From Noninvasive Testing to Treatment
www.linkedin.com
-
[ACG 2024] It's the last day of the show! Visit our team at booth #1255 to learn more about our point of care, liver assessment technology! Find us right across the floor from Madrigal Pharmaceuticals 💊 #ACG #ACG2024 #MASLD #MASH
-
-
Join us at American College of Gastroenterology 2024! Try Velacur Determined Fat Fraction our ground breaking, point of care liver assessment technology at booth 1255. Reserve your spot here: https://lnkd.in/gRgMvGTC
-
-
Sonic Incytes Medical Corp. reposted this
Fatty liver disease is extremely common, affecting an estimated 100 million – or 1 out of every 4 – Americans. Although this “silent” disease often has few noticeable symptoms, it can raise your risk of cardiovascular disease, liver failure, and liver cancer. Check out our Dr. Glen Arluk's interview below to learn more about the condition, its symptoms, risk factors, and how we can help patients manage it. https://bit.ly/3BRmKxM
-
Join us at #ACG2024 at booth 1255 for a live demo of Velacur Determined Fat Fraction our ground breaking, point of care liver assessment technology. Reserve your spot here: https://lnkd.in/gRgMvGTC
-
-
As you know, MASLD and MASH have remained challenging to manage and monitor effectively due to the limitations of existing non-invasive methods, especially those available at the point-of-care. This changes now. We’re proud to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Velacur® Determined Fat Fraction (VDFF).
FDA Grants 510(k) Clearance to Sonic Incytes' Velacur® Determined Fat Fraction (VDFF), a breakthrough for patients with MASLD and MASH
businesswire.com
-
Sonic Incytes Medical Corp. reposted this
President-Elect AACE, Emory University School of Medicine Faculty, Endocrinologist, Obesity, Lipids, Steatotic Liver Specialist at Atlanta Endocrine Associates.
MASLD and MASH require urgent attention by primary care physicians and endocrinologists. https://lnkd.in/eQHAd-36
-
-
Great initiative by American Liver Foundation, looking forward to tuning in! https://lnkd.in/gEQZwQV4 #MASLD #MASH #NAFLD #FattyLiver
American Liver Foundation Announces Fatty Liver Disease Education Program
hepmag.com